Autonomix Medical's Pancreatic Cancer Pain Study Earns SIR 2026 Featured Abstract
Event summary
- Autonomix Medical's abstract on long-term pain mitigation in pancreatic cancer selected for Featured Abstract and podium presentation at SIR 2026 Annual Scientific Meeting.
- Presentation scheduled for April 12, 2026, in Toronto, Canada, delivered by Dr. Lindsay Machan.
- Study evaluates sustained pain mitigation using transvascular RF energy-based ablation in pancreatic adenocarcinoma patients.
- Abstract highlighted in the Journal of Vascular and Interventional Radiology (JVIR) 2026 Annual Scientific Meeting Supplement.
The big picture
Autonomix Medical's selection for a Featured Abstract at SIR 2026 underscores the growing recognition of its nerve-targeted pain mitigation technology. The study's focus on long-term outcomes in pancreatic cancer addresses a critical unmet need, positioning Autonomix as a key player in the evolving landscape of minimally invasive, image-guided therapies. The company's proprietary transvascular approach could potentially disrupt traditional pain management methods, particularly if clinical validation continues to support its efficacy.
What we're watching
- Clinical Validation
- How the study's long-term pain mitigation results will impact Autonomix's regulatory and commercial strategy.
- Market Expansion
- Whether Autonomix can leverage this success to expand into other high-pain indications beyond pancreatic cancer.
- Competitive Positioning
- The pace at which Autonomix can differentiate its technology in the growing nerve-targeted treatment space.